By Fineline Cube Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced a second indication approval from China’s National Medical Products Administration (NMPA) for Denosu, the country’s first biosimilar of Amgen’s Xgeva (denosumab). The expanded approval authorizes Denosu for the treatment of solid tumor bone metastasis and multiple myeloma to delay or reduce the risk of skeletal-related events (SREs), including pathological fractures, spinal cord compression, bone radiation, or bone surgery.
Regulatory Milestone
| Item | Detail |
|---|---|
| Regulatory Agency | National Medical Products Administration (NMPA), China |
| Approval Type | Second indication expansion for approved biosimilar |
| Product | Denosu (denosumab biosimilar) |
| Reference Product | Amgen’s Xgeva (denosumab) |
| New Indications | Solid tumor bone metastasis; multiple myeloma |
| Therapeutic Objective | Delay/reduce skeletal-related events (SREs) |
| Market Status | First Xgeva biosimilar approved in China |
| Initial Approval | March 2024 – giant cell tumor of bone |
Therapeutic Profile & Clinical Significance
Skeletal-Related Events Prevention
- Target Population: Patients with bone metastases from solid tumors and multiple myeloma
- Clinical Need: High risk of debilitating SREs significantly impacting quality of life and survival
- Mechanism: Denosumab inhibits RANK ligand, reducing osteoclast-mediated bone destruction
- Efficacy Endpoint: Prevention of pathological fractures, spinal cord compression, need for bone radiation/surgery
Expanded Indication Impact
- Patient Reach: Millions of additional patients eligible for treatment beyond initial giant cell tumor indication
- Treatment Paradigm: Provides cost-effective alternative to originator Xgeva in high-volume oncology settings
- Healthcare Economics: Significant potential savings for China’s healthcare system in managing bone complications
Market Context & Commercial Strategy
Biosimilar Landscape in China
- Xgeva Market Size: Estimated at RMB 1.2 billion (USD 175 million) annually in China
- Pricing Advantage: Biosimilars typically priced 30-50% below originator products
- Reimbursement Status: Expected inclusion in provincial reimbursement formularies following indication expansion
- Competitive Position: First-mover advantage as China’s inaugural Xgeva biosimilar
Patient Population Analysis
| Indication | Annual Incidence in China | Treatment Duration | Market Potential |
|---|---|---|---|
| Solid Tumor Bone Metastasis | ~300,000 new cases | Chronic (ongoing) | High volume, sustained revenue |
| Multiple Myeloma | ~25,000 new cases | Extended treatment | Premium pricing opportunity |
| Giant Cell Tumor (Original) | ~2,000 cases | Limited duration | Orphan drug positioning |
The indication expansion transforms Denosu from an orphan drug into a mainstream oncology product with significant commercial potential.
Strategic Implications for Mabwell Bioscience
- Portfolio Validation: Demonstrates successful biosimilar development capabilities and regulatory expertise
- Revenue Diversification: Expands beyond niche giant cell tumor market to high-volume oncology indications
- Market Leadership: Establishes dominant position in China’s denosumab biosimilar segment
- International Potential: Success in China may support global regulatory filings and partnership opportunities
“This second NMPA approval significantly expands Denosu’s patient reach and therapeutic impact,” said Dr. Chen Min, CEO of Mabwell Bioscience. “As China’s first Xgeva biosimilar, Denosu now offers millions of patients with bone metastases and multiple myeloma access to this critical therapy at a more affordable price point, while maintaining the same efficacy and safety profile as the reference product.”
Forward-Looking Statements
This brief contains forward-looking statements regarding market potential, regulatory approvals, and commercial expectations. Actual results may differ due to risks including market adoption rates, pricing pressures, competitive dynamics, and healthcare policy changes in China.-Fineline Info & Tech